Upgrade to SI Premium - Free Trial

Audentes Therapeutics (BOLD) PT Raised to $44 at BMO Capital on 'AT123 Phase I & II Data... Significantly De-Risk the Program'

January 4, 2018 1:04 PM
BMO Capital raised its price target on Audentes Therapeutics (NASDAQ: BOLD) to $44.00 (from $35.00) while maintaining a Outperform ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles